SMF-216

To verify the superiority of the combination formulation over the single-agent formulation amlodipine besylate tablets (5 mg), and to evaluate the efficacy and safety of levamlodipine benazepril capsules (2.5 mg/10 mg) in patients with mild to moderate primary hypertension whose blood pressure could not be effectively controlled after 4 weeks of monotherapy with amlodipine besylate tablets (5 mg).